Ocata Therapeutics Inc fka OCAT

[rumper]

brand new, young, juvenile retinal pigment epithelium RPE


We can, ..., take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)

Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567


How long can the market ignore this success?

The market can pour 400 million dollars into Go Daddy,
a failed web site company,
but,
it has no love for a curative therapy for blindness?

"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza

Dr. Lanza

Ocata can make:
brand new, young, juvenile retinal pigment epithelium
[RPE cells] and give somebody a fresh layer of these cells

I don't believe it will be ignored forever.

The success of the phase 1/2 FDA trial,
proves that it is safe to proceed.

This not only proves the RPE therapy,
it proves Ocata has credibility.